Scientific Centre of Monaco

The Yacht Club of Monaco Celebrates the 70th Anniversary with a Packed Programme of Festivities

Retrieved on: 
Wednesday, January 11, 2023

MONACO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- January kicks off a busy events programme for 2023, as the Yacht Club de Monaco celebrates 70 years since it was set up by Prince Rainier III.

Key Points: 
  • MONACO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- January kicks off a busy events programme for 2023, as the Yacht Club de Monaco celebrates 70 years since it was set up by Prince Rainier III.
  • Presided since 1984 by HSH Prince Albert II of Monaco, this private club continues to honour its public service remit by organising world class events to promote the destination.
  • L’Art de Vivre la Mer is the motto of the Yacht Club de Monaco.
  • This edition also celebrates the 100th anniversary of the birth of Prince Rainier III, who founded YCM in 1953 and was so passionate about the sea and boats.

eureKARE to host SynBio Day 2022 entitled ‘Synthetic Biology for the Protection of our Planet’

Retrieved on: 
Monday, October 10, 2022

Since 1989, the centre has specialised in many areas linked to the environment including: marine biology, polar biology, environmental policy, astrophysics, and sustainable development.

Key Points: 
  • Since 1989, the centre has specialised in many areas linked to the environment including: marine biology, polar biology, environmental policy, astrophysics, and sustainable development.
  • Alexandre Mouradian, Chairman and Co-Founder of eureKARE, commented: Planet health is human health, and this years SynBio Day will concentrate on synthetic biology for the protection of the planet.
  • At eureKARE, we are proud to be facilitating the discussion and development of these synthetic biology applications through our annual SynBio event, and through our ventures and SynBio studios.
  • eureKARE is an investment company focused on financing and developing synthetic biology across Europe.

Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting

Retrieved on: 
Friday, August 27, 2021

The QUORUM study demonstrates the efficacy and good safety profile of firibastat.

Key Points: 
  • The QUORUM study demonstrates the efficacy and good safety profile of firibastat.
  • In severe patients with an ejection fraction less than 50%, firibastat appears to be more effective than ramipril.
  • For this reason, QUORUMs phase IIb results pave the way for a phase III clinical study in severe patients whose protocol will be finalized with a selected partner pharmaceutical company.
  • Highlights from the phase IIb QUORUM study are included below:
    295 patients were enrolled in the study within 24 hours of a first myocardial infarction.